A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL DOSE-ESCALATION RESULTS

被引：1
|
作者：
Johnson, Melissa [1 ]
Lakhani, Nehal [2 ]
Girda, Eugenia [3 ]
Olszanski, Anthony [4 ]
Fong, Lawrence [5 ]
Han, Hyunsil [6 ]
Casey, Kerry [6 ]
Li, Siyu [6 ]
Visich, Jennifer [6 ]
Skokos, Dmitris [6 ]
Seebach, Frank [6 ]
Lowy, Israel [6 ]
Fury, Matthew [6 ]
Mathias, Melissa [6 ]
Segal, Neil [7 ]
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] START Midwest, Grand Rapids, MI USA
[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[4] Fox Chase Canc Ctr, Philadelphia, PA USA
[5] Univ Calif San Francisco, San Francisco, CA USA
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0735
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
735
引用
收藏
页码：A767 / A768
页数：2
相关论文
共 50 条
  • [41] Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors
    von Mehren, M.
    Britten, C.
    Lear, K.
    Camidge, D. R.
    Wainberg, Z. A.
    Pieslor, P. C.
    Darif, M.
    Harris, S.
    Balogh, K.
    Leong, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.
    Sanborn, Rachel E.
    Bordoni, Rodolfo Eduardo
    Fleming, Gini F.
    Khasraw, Mustafa
    Hawthorne, Thomas
    Thomas, Lawrence J.
    Rawls, Tracey
    Young, Diane C.
    Golden, Philip
    Keler, Tibor
    Yellin, Michael Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Noboru Yamamoto
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shibata
    Yosuke Tamura
    Yoshitaka Seki
    Kazunori Honda
    Yuko Tanabe
    Hiroshi Wakui
    Tomohide Tamura
    Investigational New Drugs, 2017, 35 : 207 - 216
  • [44] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shibata, Takashi
    Tamura, Yosuke
    Seki, Yoshitaka
    Honda, Kazunori
    Tanabe, Yuko
    Wakui, Hiroshi
    Tamura, Tomohide
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 207 - 216
  • [45] Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
    Patnaik, Amita
    Kang, Soonmo Peter
    Tolcher, Anthony W.
    Rasco, Drew Warren
    Papadopoulos, Kyriakos P.
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Perez, Crystal
    Gergich, Kevin
    Lehnert, Manfred
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.
    Huang, Jing
    Mo, Hongnan
    Wu, Dawei
    Chen, Xuelian
    Ma, Lanying
    Lan, Bo
    Qu, Dong
    Yang, Qing
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors
    Liu, Rujiao
    Li, Wenhua
    Meng, Yanchun
    Gao, Shuiping
    Zhang, Jian
    Hu, Xichun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [48] A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors
    Friedlander, M.
    Meniawy, T.
    Markman, B.
    Mileshkin, L. R.
    Harnett, P.
    Millward, M.
    Lundy, J.
    Freimund, A. E.
    Norris, C.
    Wu, J.
    Paton, V.
    Wang, L.
    Gao, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 58 - 59
  • [49] Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
    Bendell, Johanna C.
    Bedard, Philippe
    Bang, Yung-Jue
    LoRusso, Patricia
    Hodi, Stephen
    Gordon, Michael
    D'Angelo, Sandra
    Desai, Jayesh
    Garralda, Elena
    Italiano, Antoine
    Myung-Ju Ahn
    Cervantes, Andres
    Wainberg, Zev
    Calvo, Emiliano
    Gil-Martin, Marta
    Martinez-Garcia, Maria
    Bahleda, Rastilav
    Cassier, Philippe
    Delord, Jean-Pierre
    Prawira, Amy
    Melero, Ignacio
    Emens, Leisha
    Romano, Emanuela
    Miller, Karen
    Hsieh, Robert W.
    Xue, Cloris
    Morrissey, Kari
    Twomey, Patrick
    Gash, Kelly
    Patil, Namrata S.
    Grogan, Jane
    Meng, Raymond
    Cho, Byoung
    Kim, Tae Won
    CANCER RESEARCH, 2020, 80 (16)
  • [50] Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
    Zhou, Cai
    He, Yayi
    Ren, Shengxiang
    Li, Wei
    Zhu, Jun
    Yu, Jia
    Wang, Lei
    Xiong, Anwen
    Xu, Nong
    Mao, Chenyu
    Pan, Beiqing
    Liu, Ying
    Zhou, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345